Autonomic Nervous System Drugs Practice Questions

Q: Which of the following conditions is NOT treated with a cholinomimetic agent?

Bradycardia. **Explanation:** Cholinomimetic agents (cholinergic agonists) mimic the action of acetylcholine (ACh) by stimulating muscarinic and nicotinic receptors. To answer this question, one must understand the physiological effects of Parasympathetic Nervous System (PNS) activation. **1. Why Bradycardia is the Correct Answer:** Stimulation of **M2 receptors** in the heart (specifically at the SA node) leads to a decrease in heart rate (negative chronotropy). Therefore, cholinomimetics would **worsen** bradycardia. In clinical practice, **anticholinergics** (like Atropine) are used to treat bradycardia, not cholinomimetics. **2. Why the other options are incorrect (Uses of Cholinomimetics):** * **Glaucoma:** Direct agonists like **Pilocarpine** cause miosis and contraction of the ciliary muscle, which opens the trabecular meshwork and facilitates the drainage of aqueous humor, reducing intraocular pressure. * **Myasthenia Gravis:** This condition involves autoantibodies against NMJ nicotinic receptors. Indirect cholinomimetics (AChE inhibitors) like **Pyridostigmine** or **Neostigmine** increase the concentration of ACh at the synaptic cleft, improving muscle strength. * **Post-surgical Atony/Ileus:** Drugs like **Bethanechol** (a muscarinic agonist) stimulate **M3 receptors** in the GI tract and bladder, promoting peristalsis and bladder emptying in non-obstructive conditions. **High-Yield NEET-PG Pearls:** * **Bethanechol:** "B" for Bowel and Bladder (used for postoperative ileus/urinary retention). * **Pilocarpine:** Drug of choice for acute angle-closure glaucoma. * **Edrophonium:** A short-acting AChE inhibitor used in the **Tensilon Test** for diagnosing Myasthenia Gravis (though largely replaced by antibody testing). * **Contraindications:** Cholinomimetics should be avoided in patients with **Asthma** (causes bronchoconstriction) and **Peptic Ulcer Disease** (increases gastric acid secretion).

Q: Which cholinergic receptor is the primary target for drugs used to treat urinary incontinence in neurogenic bladder?

M3. ### Explanation **Correct Option: C (M3)** The primary goal in treating urinary incontinence (specifically urge incontinence or overactive bladder) is to reduce the involuntary contractions of the **detrusor muscle**. * **Mechanism:** The detrusor muscle contains both M2 and M3 receptors. However, the **M3 receptor** is the functionally dominant subtype responsible for bladder contraction [1]. * **Action:** Activation of M3 receptors (via Gq protein) leads to increased intracellular calcium, causing detrusor contraction and bladder emptying. Therefore, **M3 antagonists** (e.g., Oxybutynin, Darifenacin, Solifenacin) are used to promote bladder relaxation and increase storage capacity [1], [2]. **Incorrect Options:** * **A (M1):** These receptors are primarily located in the CNS and gastric parietal cells [3]. They are involved in memory and gastric acid secretion, not bladder contraction. * **B (M2):** While M2 receptors are numerically more abundant in the bladder than M3, they primarily function by inhibiting adenylate cyclase (Gi). Their role in direct contraction is secondary to M3; they mainly counteract sympathetically mediated relaxation [1]. * **D (M4):** These are primarily found in the CNS (striatum) and are involved in modulating locomotor activity and dopamine release, with no significant role in bladder dynamics. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** **Oxybutynin** is a classic non-selective muscarinic antagonist, while **Darifenacin** and **Solifenacin** are M3-selective, offering fewer systemic side effects (like dry mouth/xerostomia) [1], [2]. * **Mirabegron:** A newer alternative for overactive bladder that acts as a **β3-agonist**, promoting bladder relaxation. * **Contraindication:** Antimuscarinics should be avoided in patients with **narrow-angle glaucoma** and **benign prostatic hyperplasia (BPH)** due to the risk of acute urinary retention.

Q: Which of the following is the most uroselective anticholinergic drug?

Darifenacin. **Explanation:** **Darifenacin** is the correct answer because it is a highly selective **M3 receptor antagonist**. The M3 muscarinic receptors are primarily responsible for bladder detrusor muscle contraction. By selectively blocking these receptors, Darifenacin reduces bladder overactivity with a lower incidence of systemic side effects (like dry mouth or blurred vision) compared to non-selective agents like Oxybutynin. It is specifically indicated for Overactive Bladder (OAB). **Analysis of Incorrect Options:** * **Tolbutamide:** This is a **First-generation Sulfonylurea** used in the management of Type 2 Diabetes Mellitus. It acts by stimulating insulin release from pancreatic beta cells and has no anticholinergic properties. * **Duloxetine:** This is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**. While it is used in the treatment of Stress Urinary Incontinence (SUI) by increasing the tone of the external urethral sphincter via Onuf’s nucleus, it is not an anticholinergic. * **Tamsulosin:** This is a **selective Alpha-1A blocker**. It is used in Benign Prostatic Hyperplasia (BPH) to relax the smooth muscles of the bladder neck and prostate. It is "uroselective" for alpha receptors, but it is not an anticholinergic drug. **High-Yield Clinical Pearls for NEET-PG:** * **M3 Selective Anticholinergics:** Darifenacin and Solifenacin (Mnemonic: **D**ari-**S**oli are **M3** holy). * **Non-selective Anticholinergics for OAB:** Oxybutynin, Tolterodine, Trospium, and Fesoterodine. * **Mirabegron:** A Beta-3 agonist used for OAB; it is a preferred alternative if anticholinergics are contraindicated (e.g., in narrow-angle glaucoma). * **Drug of choice for Enuresis:** Desmopressin (Non-pharmacological: Bed-wetting alarms).

Q: Organophosphates bind to which site of acetylcholinesterase?

Esteratic site. ### Explanation **Mechanism of Action:** Acetylcholinesterase (AChE) is the enzyme responsible for the hydrolysis of acetylcholine (ACh). It possesses two primary functional domains: the **Anionic site** (which attracts the positive quaternary ammonium group of ACh) and the **Esteratic site** (which contains a serine residue responsible for the actual cleavage of the ester bond). **Organophosphates (OPs)** are irreversible inhibitors that function by phosphorylating the serine hydroxyl group at the **Esteratic site**. This creates a stable covalent bond that prevents the enzyme from breaking down acetylcholine, leading to a "cholinergic crisis." **Analysis of Options:** * **Option A (Anionic site):** This site primarily binds the choline moiety of ACh. Drugs like **Edrophonium** (a reversible anticholinesterase) bind non-covalently to the anionic site. OPs do not bind here. * **Option B (Esteratic site):** Correct. OPs form a covalent phosphate-enzyme complex at this site. * **Option C (Acetylcholine):** This is the endogenous substrate, not a binding site on the enzyme itself. **Clinical Pearls for NEET-PG:** 1. **Aging:** Over time, the OP-enzyme bond strengthens (loss of an alkyl group), making it irreversible. This process is called "Aging." 2. **Pralidoxime (2-PAM):** Known as a "Cholinesterase Reactivator," it can break the OP-enzyme bond, but **only before aging occurs**. It works by displacing the phosphate group from the esteratic site. 3. **Atropine:** The specific antidote for the muscarinic effects of OP poisoning; it does not reactivate the enzyme but blocks the excess ACh at the receptor level. 4. **Carbamates vs. OPs:** Carbamates (like Neostigmine) also bind to the esteratic site but are reversible and do not undergo "aging."

Q: Dexmedetomidine is a

Centrally acting alpha 2 agonist. **Explanation:** **Dexmedetomidine** is a highly selective **alpha-2 ($\alpha_2$) adrenergic agonist**. Its primary site of action is the **Locus Coeruleus** in the brainstem (pons). By stimulating central $\alpha_2$ receptors, it inhibits the release of norepinephrine, leading to a state of "conscious sedation" and analgesia. * **Why Option A is Correct:** Dexmedetomidine acts **centrally** on $\alpha_2$ receptors. Unlike Clonidine, it is 8 to 10 times more selective for the $\alpha_2$ receptor, making it a potent sedative and anesthetic adjuvant. It produces sedation that mimics natural sleep, where patients remain easily arousable. * **Why Options B & D are Incorrect:** While $\alpha_2$ receptors exist peripherally (causing transient initial vasoconstriction), the therapeutic effects of Dexmedetomidine (sedation, sympatholysis, and bradycardia) are mediated through the **Central Nervous System (CNS)**. It is not an antagonist; an example of an $\alpha_2$ antagonist is Yohimbine. * **Why Option C is Incorrect:** Dexmedetomidine is an **agonist**, not an antagonist. Antagonists would block the receptor and typically increase sympathetic outflow. **High-Yield Clinical Pearls for NEET-PG:** 1. **Unique Property:** It causes **"Conscious Sedation"**—the patient is sedated but can be easily awakened to follow commands. 2. **Respiratory Safety:** Unlike opioids or benzodiazepines, it causes **minimal respiratory depression**, making it ideal for ICU sedation and awake intubation. 3. **Side Effects:** The most common side effects are **bradycardia** and **hypotension** due to decreased central sympathetic outflow. 4. **Clinical Use:** Used for short-term ICU sedation, premedication, and as an adjunct in spinal/epidural anesthesia to prolong the block duration.

Q: What is the mechanism of action of oximes?

Reactivating cholinesterase. **Explanation:** **Mechanism of Action:** Oximes (such as **Pralidoxime/2-PAM** and Obidoxime) are known as **cholinesterase reactivators** [1], [3]. In organophosphate (OP) poisoning, the organophosphate compound binds to the esteratic site of the acetylcholinesterase (AChE) enzyme, phosphorylating it and rendering it inactive. This leads to an accumulation of acetylcholine. Oximes have a high affinity for the phosphorus atom; they bind to the OP-enzyme complex, nucleophilically attack the phosphate bond, and pull the phosphate group away, thereby freeing and **reactivating the cholinesterase enzyme** [1], [3]. **Analysis of Options:** * **Option A & D:** Oximes do not act directly on cholinergic receptors (nicotinic or muscarinic). Their primary target is the enzyme itself. * **Option C:** Inhibiting cholinesterase is the mechanism of the poison (Organophosphates/Carbamates), not the antidote. **High-Yield Clinical Pearls for NEET-PG:** 1. **The "Aging" Phenomenon:** Oximes must be administered early. If the OP-enzyme bond "ages" (dealkylation), the bond becomes permanent, and oximes can no longer reactivate the enzyme [2], [3]. 2. **Blood-Brain Barrier:** Pralidoxime is a quaternary ammonium compound and **does not cross the BBB**. Therefore, it does not reverse central CNS symptoms (Atropine is required for this). 3. **Specific Contraindication:** Oximes are generally **not recommended in Carbamate poisoning** (e.g., Neostigmine, Physostigmine) because the carbamoyl-enzyme complex dissociates quickly on its own, and oximes may actually worsen the inhibition. 4. **Clinical Use:** They are specifically effective against the **nicotinic effects** (muscle fasciculations and paralysis) of OP poisoning, whereas Atropine handles the muscarinic effects.

Q: Which one of the following neurotransmitters acts commonly on both the parasympathetic and sympathetic divisions of the autonomic nervous system?

Acetylcholine. ### Explanation **Correct Answer: C. Acetylcholine** **Why it is correct:** Acetylcholine (ACh) is the primary neurotransmitter that bridges both divisions of the Autonomic Nervous System (ANS). It acts at three key sites across both systems: 1. **Preganglionic Neurons:** ACh is the neurotransmitter for all preganglionic fibers in both the sympathetic and parasympathetic nervous systems, acting on **Nicotinic (Nn)** receptors in the ganglia. 2. **Parasympathetic Postganglionic Neurons:** It acts on **Muscarinic** receptors at the effector organs. 3. **Sympathetic Exceptions:** ACh is also the neurotransmitter for sympathetic postganglionic fibers supplying **sweat glands** (thermoregulatory) and some blood vessels in skeletal muscles. **Why the other options are incorrect:** * **A. Atropine:** This is not a neurotransmitter; it is a competitive **muscarinic antagonist** (drug) used to block parasympathetic effects. * **B. Pilocarpine:** This is a **muscarinic agonist** (cholinomimetic drug), not an endogenous neurotransmitter. It is primarily used in the treatment of glaucoma and xerostomia. * **D. Adrenaline (Epinephrine):** While it is a neurotransmitter/hormone, it acts almost exclusively on the **sympathetic** division (Adrenergic receptors). It has no physiological role in the parasympathetic ganglia or postganglionic terminals. **NEET-PG High-Yield Pearls:** * **The "All-Preganglionic" Rule:** Remember that *all* autonomic preganglionic fibers (Sympathetic + Parasympathetic) and the fibers to the **Adrenal Medulla** are cholinergic. * **Somatic Nervous System:** ACh is also the neurotransmitter at the Neuromuscular Junction (NMJ), acting on **Nm** receptors. * **Sweat Glands Exception:** This is a favorite "catch" in exams—sweat glands are anatomically sympathetic but pharmacologically cholinergic.

Q: Botulinum toxin acts by:

Inhibiting acetylcholine release.. Explanation: **Mechanism of Action:** Botulinum toxin, produced by the bacterium *Clostridium botulinum*, is a potent neurotoxin that causes flaccid paralysis [2]. It acts presynaptically at the neuromuscular junction [4]. The toxin is a protease that cleaves **SNARE proteins** (specifically SNAP-25, synaptobrevin, or syntaxin), which are essential for the fusion of acetylcholine (ACh) vesicles with the neuronal membrane. By preventing this fusion, the toxin effectively **inhibits the release of acetylcholine** into the synaptic cleft [2], [4]. **Analysis of Options:** * **Option A (Incorrect):** The synthesis of ACh (mediated by Choline Acetyltransferase) is not affected by Botulinum toxin. Hemicholinium is a drug that interferes with synthesis by blocking choline uptake [1], [3]. * **Option C (Incorrect):** The toxin prevents secretion/release rather than promoting it. Drugs like Black Widow Spider Venom (alpha-latrotoxin) cause the massive *release* of ACh. * **Option D (Incorrect):** Option B is the established mechanism. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Uses:** Used for focal dystonias (Blepharospasm, Torticollis), Achalasia cardia, Hyperhidrosis (excessive sweating), and cosmetic reduction of wrinkles. * **Botulism:** Food-borne botulism (ingestion of preformed toxin) or Infant botulism (ingestion of spores from honey, known as "Floppy Baby Syndrome"). * **Antidote:** Guanidine or 4-Aminopyridine can sometimes be used to increase ACh release, but treatment is primarily supportive with antitoxin. * **Contrast:** Unlike Botulinum, **Tetanus toxin** (which also cleaves SNARE proteins) travels retrogradely to the CNS to inhibit GABA/Glycine release, leading to spastic paralysis [2].

Q: Which of the following antagonizes the visceral side effects of neostigmine used in the reversal of d-tubocurarine blockade?

Atropine. **Explanation:** **1. Why Atropine is the Correct Answer:** Neostigmine is an acetylcholinesterase inhibitor used to reverse the neuromuscular blockade caused by non-depolarizing agents like d-tubocurarine. By inhibiting the breakdown of acetylcholine (ACh), it increases ACh levels at both **nicotinic** and **muscarinic** receptors. While the action at nicotinic receptors (NMJ) restores muscle power, the action at muscarinic receptors causes unwanted **visceral side effects** (parasympathetic overactivity) such as bradycardia, excessive salivation, bronchospasm, and increased GI motility. **Atropine**, a muscarinic antagonist, is co-administered to selectively block these visceral effects without interfering with the desired nicotinic action at the skeletal muscles. **2. Why Other Options are Incorrect:** * **Nicotine:** This is a nicotinic agonist. It would not antagonize the muscarinic side effects and could potentially worsen autonomic instability. * **Pilocarpine:** This is a muscarinic agonist. It would exacerbate the side effects of neostigmine (e.g., further increasing secretions and bradycardia). * **Pyridostigmine:** This is another acetylcholinesterase inhibitor (similar to neostigmine). It would worsen the cholinergic crisis rather than antagonizing the side effects. **3. High-Yield Clinical Pearls for NEET-PG:** * **Glycopyrrolate** is often preferred over Atropine in clinical practice because it is polar (does not cross the blood-brain barrier) and has a heart rate matching profile closer to neostigmine. * **Neostigmine** is preferred over Physostigmine for reversal because it has a stronger action on the NMJ and does not cross the BBB. * **Rule of Thumb:** Always pair an anticholinesterase (Neostigmine) with an anticholinergic (Atropine/Glycopyrrolate) to prevent "vagal arrest" during anesthesia reversal.

Q: Which is the shortest acting beta-blocker?

Esmolol. **Explanation:** **Esmolol** is the shortest-acting beta-blocker due to its unique chemical structure. It is an ester, which allows it to be rapidly hydrolyzed by **red blood cell esterases** (not plasma cholinesterase). This results in an ultra-short half-life of approximately **9 minutes**. Because of this rapid metabolism, it must be administered via intravenous infusion and is easily titratable; if side effects occur, they resolve quickly once the infusion is stopped. **Analysis of Incorrect Options:** * **Propranolol:** A prototype non-selective beta-blocker with a half-life of 3–4 hours. It is lipid-soluble and undergoes significant first-pass metabolism. * **Timolol:** A non-selective beta-blocker primarily used topically for glaucoma. Its systemic half-life is approximately 4 hours. * **Atenolol:** A cardioselective (Beta-1) blocker that is water-soluble (hydrophilic) and excreted unchanged by the kidneys. It has a half-life of 6–9 hours, allowing for once-daily dosing. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Esmolol is the drug of choice for intraoperative tachycardia, hypertensive emergencies (especially aortic dissection), and supraventricular arrhythmias where rapid control is needed. * **Selectivity:** It is a **cardioselective (Beta-1)** antagonist. * **Metabolism:** Remember it is metabolized by **RBC esterases**. This makes it safe to use in patients with liver or kidney dysfunction. * **Longest acting beta-blocker:** Nadolol (half-life of 14–24 hours).

Question 1

Which of the following conditions is NOT treated with a cholinomimetic agent?

Accepted Answer

Bradycardia

Answer

Glaucoma

Answer

Myasthenia gravis

Answer

Post-surgical atony or ileus

Question 2

Which cholinergic receptor is the primary target for drugs used to treat urinary incontinence in neurogenic bladder?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

M4

Question 3

Which of the following is the most uroselective anticholinergic drug?

Accepted Answer

Darifenacin

Answer

Tolbutamide

Answer

Duloxetine

Answer

Tamsulosin

Question 4

Organophosphates bind to which site of acetylcholinesterase?

Accepted Answer

Esteratic site

Answer

Anionic site

Answer

Acetylcholine

Answer

None of the above

Question 5

Dexmedetomidine is a

Accepted Answer

Centrally acting alpha 2 agonist

Answer

Peripherally acting alpha2 agonist

Answer

Centrally acting alpha 2 antagonist

Answer

Peripherally acting alpha 2 antagonist

Question 6

What is the mechanism of action of oximes?

Accepted Answer

Reactivating cholinesterase

Answer

Inhibiting cholinergic receptors

Answer

Inhibiting cholinesterase

Answer

Reactivating cholinergic receptors

Question 7

Which one of the following neurotransmitters acts commonly on both the parasympathetic and sympathetic divisions of the autonomic nervous system?

Accepted Answer

Acetylcholine

Answer

Atropine

Answer

Pilocarpine

Answer

Adrenaline

Question 8

Botulinum toxin acts by:

Accepted Answer

Inhibiting acetylcholine release.

Answer

Synthesis of acetylcholine.

Answer

Secretion of acetylcholine.

Answer

None of the above.

Question 9

Which of the following antagonizes the visceral side effects of neostigmine used in the reversal of d-tubocurarine blockade?

Accepted Answer

Atropine

Answer

Nicotine

Answer

Pilocarpine

Answer

Pyridostigmine

Question 10

Which is the shortest acting beta-blocker?

Accepted Answer

Esmolol

Answer

Propranolol

Answer

Timolol

Answer

Atenolol

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?